Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients
Eli Lilly Halts Antibody Trial in Hospitalized COVID-19 Patients

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

  1. Home
  2. Subjects
  3. monoclonal antibodies
monoclonal antibodies
A Greener Recombinant Monoclonal Antibody
A Greener Recombinant Monoclonal Antibody
The Scientist Creative Services Team | Dec 9, 2020
Learn more about environmentally-friendly antibodies that deliver superior performance.
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Antibody-Based Drug May Reduce COVID-19 Hospitalizations: Study
Lisa Winter | Sep 17, 2020
Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.
Bacterial Superglue Enables Antiviral Antibody Discovery
Bacterial Superglue Enables Antiviral Antibody Discovery
Ruth Williams | Jul 13, 2020
Testing out combinations of antiviral proteins from llamas could help researchers create potent virus-neutralizing multimers.
Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies
Putting the Brakes on SARS-CoV-2: Neutralizing Antibodies
The Scientist Creative Services Team | Jul 6, 2020
Experts will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.
First Antibody Trial Launched in COVID-19 Patients
First Antibody Trial Launched in COVID-19 Patients
Katarina Zimmer | Jun 2, 2020
In record time, scientists have gone from harvesting antibodies against SARS-CoV-2 from survivors of coronavirus infections to testing the antibodies’ safety as a drug in humans.
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Scientists Scan for Weaknesses in the SARS-CoV-2 Spike Protein
Chris Baraniuk | Apr 9, 2020
The virus’s tool for prying open host cells is coated in a protective armor of sugar—but gaps may offer vulnerability to disruption by antibodies.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Two Experimental Drugs Effective at Treating Ebola
Two Experimental Drugs Effective at Treating Ebola
Catherine Offord | Aug 13, 2019
REGN-EB3 and mAb114 reduced mortality in a clinical trial carried out during the ongoing outbreak in Democratic Republic of Congo.
MIT Researcher Allegedly Copied Other Groups’ Drug Designs
MIT Researcher Allegedly Copied Other Groups’ Drug Designs
Catherine Offord | May 29, 2019
Executives at a biotech that develops new antibodies argue that Ram Sasisekharan didn’t come up with the structures for at least two experimental therapies that his group has described.